REGENXBIO, Inc. (RGNX)
8.69
-0.55
(-5.95%)
USD |
NASDAQ |
Mar 03, 16:00
8.69
0.00 (0.00%)
Pre-Market: 08:49
REGENXBIO Research and Development Expense (Annual) : 192.31M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Sarepta Therapeutics, Inc. | 1.496B |
| BioMarin Pharmaceutical, Inc. | 700.97M |
| Omeros Corp. | 119.52M |
| Ultragenyx Pharmaceutical, Inc. | 723.00M |
| CytomX Therapeutics, Inc. | 81.76M |